Review of current status of targeted alpha therapy in cancer treatment

Abstract

Targeted alpha therapy is an emerging alternative for palliative therapy of a wide range of tumor types. Data from preclinical and clinical research demonstrates a high potential for the selective killing of tumor cells and minimal toxicity to surrounding healthy tissues. This article summarizes the developmental stages of alpha-targeted therapy from benchtop to commercialization. It discusses fundamental properties, production pathways, microdosimetry, and possible targeting vectors. Proper coverage has also been given to comparing it with other standard treatment procedures while exploring clinical applications of alpha emitters. In the end, like other therapies, the challenges it faces and its future impact on personalized medicine are also illustrated.